Mivacron (Mivacurium Chloride)

Mivacurium, the active ingredient in Mivacron, is a non‑depolarizing neuromuscular blocking agent presented as a sterile injectable solution for intravenous use. It provides short‑acting skeletal muscle relaxation to facilitate endotracheal intubation and to support muscle relaxation during surgical procedures.

GNH USA supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, adhering to stringent quality standards and providing reliable global distribution for clinical use.

Mivacron is a short‑acting neuromuscular blocker used in anesthesia to achieve rapid muscle relaxation.

- Facilitation of endotracheal intubation: provides brief skeletal muscle relaxation allowing safe tube placement. - Muscle relaxation during surgery: enables controlled relaxation of skeletal muscles throughout operative procedures. - Diagnostic procedures requiring short‑acting blockade: allows temporary paralysis for specific investigations such as electromyography.

Mivacron may be associated with several adverse reactions, ranging from frequent, mild events to rare, serious conditions.

Common Side Effects: - Flushing: transient redness of the skin, often on the face or neck. - Bronchospasm: narrowing of the airways causing wheezing. - Hypotension: temporary drop in blood pressure. - Nausea: feeling of sickness or urge to vomit.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction that can be life‑threatening. - Prolonged apnea: extended inability to breathe requiring ventilatory support. - Cardiac arrhythmia: abnormal heart rhythm that may be dangerous.

When using Mivacron, clinicians should observe specific precautions to minimize risk and ensure optimal drug performance.

- Renal impairment: monitor for prolonged neuromuscular blockade as clearance may be reduced. - Hepatic disease: consider possible extension of drug effect due to altered plasma cholinesterase activity. - Known hypersensitivity: avoid administration in patients with documented allergy to mivacurium or related compounds. - Concurrent cholinesterase inhibitors: may prolong paralysis; adjust monitoring accordingly. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mivacron can interact with other agents that affect neuromuscular transmission or cardiovascular stability.

Major Interactions (Avoid): - Cholinesterase inhibitors (e.g., neostigmine, pyridostigmine): may significantly prolong neuromuscular blockade. - Aminoglycoside antibiotics (e.g., gentamicin, streptomycin): potentiate muscle relaxation and increase risk of respiratory failure. - Magnesium sulfate: enhances the blocking effect and can lead to profound paralysis.

Moderate Interactions (Monitor Closely): - Inhalational anesthetics (e.g., sevoflurane, desflurane): additive muscle relaxation may extend duration. - Volatile anesthetics: may increase the intensity of blockade, requiring dose adjustment. - Beta‑adrenergic blockers: can affect hemodynamic response during induction.